Protein kinases, the largest family of human enzymes, are now considered by many to be the largest druggable target class. Encompassing well over 500 proteins (2% of the human genome), kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers and autoimmune and inflammatory diseases.

The protein kinase family represents a wealth of potential new drug targets. However, despite the promise, progress in kinase related drug discovery has been significantly challenged by several key factors. These include the sheer number and homology of kinases in the genome, as well as the complexity of the cellular pathways that they regulate, which have made it difficult to define the functions of individual kinases, and therefore to select the right kinase targets for drug discovery. CGI’s proprietary chemical genetics technologies were expressly developed to provide unique, definitive solutions to the major challenges of kinase drug discovery and make kinase drug discovery and development more effective and efficient.

CGI has built a powerful drug discovery engine that specifically addresses the unique challenges associated with kinase targets. Integrating its expertise in kinase biology with extensive chemistry and drug development capabilities, CGI is emerging as a leader in developing breakthrough kinase inhibitor therapeutics.